Geneos Wealth Management’s Kyntra Bio KYNB Stock Holding History

Geneos Wealth Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4	Closed	-$1K	–	2044
2022 Q3	$1K	Buy	+4	New	+$1.29K	﹤0.01%	1921

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Geneos Wealth Management's KYNB Position: Q4 2022 in Review

Geneos Wealth Management sold out of Kyntra Bio (KYNB) in Q4 2022, closing a stake of 4 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in KYNB in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 144 funds tracked by Wall St. Rank hold KYNB as of Q4 2022.

Geneos Wealth Management reported no remaining Kyntra Bio position as of Q4 2022 after selling out during the quarter.
Geneos Wealth Management sold 4 Kyntra Bio shares in Q4 2022, an estimated $1K.
Geneos Wealth Management first reported a position in Kyntra Bio in Q3 2022 and held it in 1 quarter.
Geneos Wealth Management's Kyntra Bio position peaked at $1K in Q3 2022.
144 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2022.

Based on Geneos Wealth Management's 13F filing for Q4 2022, filed 31 Jan 2023.